Penumbra (PEN) Surpasses Q2 Earnings and Revenue Estimates

Company Performance - Penumbra reported quarterly earnings of $0.86 per share, exceeding the Zacks Consensus Estimate of $0.81 per share, and up from $0.64 per share a year ago, representing an earnings surprise of +6.17% [1] - The company posted revenues of $339.46 million for the quarter ended June 2025, surpassing the Zacks Consensus Estimate by 3.54%, and an increase from $299.4 million year-over-year [2] - Over the last four quarters, Penumbra has consistently surpassed consensus EPS and revenue estimates [2] Stock Outlook - Penumbra shares have declined approximately 3.1% since the beginning of the year, while the S&P 500 has gained 8.6% [3] - The company's current Zacks Rank is 3 (Hold), indicating expected performance in line with the market in the near future [6] - The consensus EPS estimate for the upcoming quarter is $0.96 on revenues of $341.93 million, and for the current fiscal year, it is $3.72 on $1.35 billion in revenues [7] Industry Context - The Medical - Instruments industry, to which Penumbra belongs, is currently ranked in the bottom 37% of over 250 Zacks industries, suggesting potential challenges ahead [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which could impact Penumbra's stock performance [5]